Our Portfolio

Current and Prior Investments

Strategy:

Alto Pharmacy

https://www.alto.com/

Investment Year: 2023

A full-service, digitally-powered pharmacy providing an easier, more supportive and more affordable pharmacy experience.

Tourmaline Bio

https://www.tourmalinebio.com/

Investment Year: 2023

Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

Completed reverse merger in 2023

PBS Biotech

https://www.pbsbiotech.com/

Investment Year: 2022

Commercial-stage life science company focused on manufacturing scalable single-use bioreactors and providing process development services to cell therapy clients.

Escient Pharmaceuticals

https://www.escientpharma.com/

Investment Year: 2022

Clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders.

Acquired by Incyte in 2024

AtomVie

https://www.atomvie.com/

Investment Year: 2022

Global contract development and manufacturing organization for radiotherapeutics.

Health Outlook

https://www.healthoutlook.com/

Investment Year: 2022

Health prediction company utilizing proteomics and advanced statistical techniques to better predict and improve health outcomes.

Xcell Biosciences

https://www.xcellbio.com/

Investment Year: 2022

Commercial-stage life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing.

Ellie Diagnostics

https://elliediagnostics.com/

Investment Year: 2021

Disruptive animal health provider delivering innovative diagnostic solutions to veterinarians and pet owners across the United States.

Antios Therapeutics

Investment Year: 2021

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Jasper Therapeutics

https://www.jaspertherapeutics.com/

Investment Year: 2021

Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.

Merged with Amplitude Healthcare Acquisition Corporation in 2021

Caribou Biosciences

https://www.cariboubio.com/

Investment Year: 2021

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Ribon Therapeutics

https://ribontx.com/

Investment Year: 2021

Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.

Arch Oncology

Investment Year: 2021

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Immunocore

https://www.immunocore.com/

Investment Year: 2020

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021

Amber Ophthalmics

https://www.amberophthalmics.com/

Investment Year: 2020

Clinical-stage ophthalmic company focused on novel therapeutics to address unmet medical needs, providing for the restoration, preservation, and improvement of patient vision and quality of life.

Acquired by a strategic in 2024

Sebela Pharmaceuticals

https://sebelapharma.com/

Investment Year: 2018

Commercial-stage specialty pharmaceutical company focused on gastrointestinal, dermatological, and women’s health products.

Meridien Research

Investment Year: 2018

Clinical trial site services company operating an integrated network of research sites in the Southeast United States.

Eyevance Pharmaceuticals

Investment Year: 2017

Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.

Acquired by Santen in 2020

Sentynl Therapeutics

Investment Year: 2015

Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.

Acquired by Zydus in 2017

Saol Therapeutics

https://saolrx.com/

Investment Year: 2015

Clinical-stage therapeutics company focused on the central nervous system (CNS), orphan diseases, and conditions with high unmet medical need.

FOR VELAN HOLDINGS PLEASE SEE OUR 13F FILINGS.